Physician profile
Dat T Vo
NPI 1780004523
$2,280.34
in general payments reported to CMS, 2019-2025
23 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.83 · 2023: $951 · 2024: $855 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $961.43 | 2023-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Brainlab, INC. | $255.65 | 2023 | Image Guided Surgical Device |
| Astrazeneca Pharmaceuticals Lp | $204.04 | 2023-2025 | Enhertu, Imfinzi |
| Eisai INC. | $156.61 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $97.11 | 2024 | Provenge |
| Karyopharm Therapeutics INC. | $71.68 | 2024-2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $56.48 | 2024-2025 | |
| Daiichi Sankyo INC. | $56.17 | 2023-2024 | Enhertu |
| Incyte Corporation | $49.91 | 2025 | Monjuvi |
| Pfizer INC. | $47.28 | 2024-2025 | |
| Amgen INC. | $44.80 | 2023-2024 | Prolia, Evenity |
| Regeneron Healthcare Solutions, INC. | $36.40 | 2024 | Libtayo |
| Fresenius Kabi USA, LLC | $36.11 | 2024 | Stimufend |
| Boston Scientific Corporation | $26.83 | 2019 | |
| Merck Sharp & Dohme LLC | $24.44 | 2024 | Keytruda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $22.77 | 2023 | Somatom Go.Top |
| Exelixis INC. | $21.90 | 2025 | Cabometyx |
| Alnylam Pharmaceuticals INC. | $21.67 | 2024 | Givlaari |
| Mirati Therapeutics, INC. | $19.36 | 2023 | Krazati |
| Morphosys, US INC. | $19.35 | 2024 | Monjuvi |
| Gilead Sciences, INC. | $18.55 | 2025 | Trodelvy |
| Abbvie INC. | $16.87 | 2024 | |
| Bioprotect Medical, INC. | $14.93 | 2025 | Bioprotect Balloon Implant System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.